Search Results - "Mir, Roser"

Liposomes Co-Encapsulating Cisplatin/Mifepristone Improve the Effect on Cervical Cancer: In Vitro and In Vivo Assessment by Ledezma-Gallegos, Fabricio, Jurado, Rafael, Mir, Roser, Medina, Luis Alberto, Mondragon-Fuentes, Laura, Garcia-Lopez, Patricia

“…Cervical cancer is usually diagnosed in the later stages despite many campaigns for early detection and continues to be a major public health problem. The…”
Get full text

Real-World Efficacy and Safety of Plasma-Derived Von Willebrand Factor-Containing Factor VIII Concentrates in Patients With Von Willebrand Disease in Italy by Federici, Augusto B, Santoro, Rita Carlotta, Santoro, Cristina, Pieri, Lisa, Santi, Roberto Mario, Barillari, Giovanni, Borchiellini, Alessandra, Tosetto, Alberto, Zanon, Ezio, De Cristofaro, Raimondo, Mairal, Esther, Mir, Roser

“…Plasma-derived von Willebrand factor-containing factor VIII concentrates (pd-VWF/FVIII-C) are the mainstay of treatment in von Willebrand disease (VWD)…”
Get full text

Clinical Efficacy and Safety of Fanhdi®, a Plasma-Derived VWF/Factor VIII Concentrate, in von Willebrand Disease in Spain: A Retrospective Study by Jiménez-Yuste, Víctor, Alvarez-Román, María Teresa, Palomo Bravo, Ángeles, Galmes, Bernardo J., Nieto Hernández, Maria del Mar, Benítez Hidalgo, Olga, Marzo Alonso, Cristina, Pérez González, Noelia Florencia, Coll, Julia, Núñez, Ramiro, Carrasco, Marina, García Candel, Faustino, Gonzalez-Porras, Jose Ramon, Hernández García, Carmen, Varó Castro, Maria José, Mir, Roser

“…Objective To evaluate the efficacy and safety of a plasma-derived factor VIII concentrate containing von Willebrand Factor (pdVWF/FVIII) in standard clinical…”
Get full text

Derivation of a Pharmacokinetic Model to Include a Plasma-Derived, von Willebrand Factor-Containing Factor VIII (Koate®-DVI) Concentrate and its Low-Dose Use by Hajducek, Dagmar M., Primacakti, Fitri, Chozie, Novie, Mir, Roser, McEneny-King, Alanna, Iorio, Alfonso, Edginton, Andrea

“…Background Population pharmacokinetics (popPK) has been reliably leveraged to generate individual PK in hemophilia patients. Specific popPK models are suited…”
Get full text

Creating a Population Model for PK-Tailored Dosing Using Real-World Data from the Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo) Platform by Chelle, Pierre, Yeung, Cindy, Bonanad Boix, Santiago, Morales, Juan Cristobal, Ozelo, Margareth C, Megias Vericat, Juan E., Iorio, Alfonso, Spears, Jeffrey, Mir, Roser, Edginton, Andrea N

“…Objective: The Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo) platform allows hemophilia treaters to estimate individual PK…”
Get full text

YM155 sensitizes ovarian cancer cells to cisplatin inducing apoptosis and tumor regression by Mir, Roser, Stanzani, Elisabetta, Martinez-Soler, Fina, Villanueva, Alberto, Vidal, August, Condom, Enric, Ponce, Jordi, Gil, Joan, Tortosa, Avelina, Giménez-Bonafé, Pepita

“…Abstract Objective The objective of this study is to chemosensitize ovarian cancer (OVCa) cells to cisplatin (CDDP) using an inhibitor of Survivin, YM155. The…”
Get full text

Antihormonal agents as a strategy to improve the effect of chemo-radiation in cervical cancer: in vitro and in vivo study by Segovia-Mendoza, Mariana, Jurado, Rafael, Mir, Roser, Medina, Luis A, Prado-Garcia, Heriberto, Garcia-Lopez, Patricia

“…Over the past few years, the concurrent use of cisplatin-based chemotherapy and radiation therapy has dramatically improved the local response and increased…”
Get full text

Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild‐type ovarian cancer cells by Mir, Roser, Tortosa, Avelina, Martinez‐Soler, Fina, Vidal, August, Condom, Enric, Pérez‐Perarnau, Alba, Ruiz‐Larroya, Tatiana, Gil, Joan, Giménez‐Bonafé, Pepita

“…Ovarian cancer (OVCa) is the leading cause of death from gynecological malignancies. Although treatment for advanced OVCa has improved with the introduction of…”
Get full text

Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients by Chelle, Pierre, Yeung, Cindy H. T., Bonanad, Santiago, Morales Muñoz, Juan Cristóbal, Ozelo, Margareth C., Megías Vericat, Juan Eduardo, Iorio, Alfonso, Spears, Jeffrey, Mir, Roser, Edginton, Andrea

“…Fanhdi/Alphanate is a plasma derived factor VIII concentrate used for treating hemophilia A, for which there has not been any dedicated model describing its…”
Get full text

Correction to: Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients by Chelle, Pierre, Yeung, Cindy H. T., Bonanad, Santiago, Morales Muñoz, Juan Cristóbal, Ozelo, Margareth C., Megías Vericat, Juan Eduardo, Iorio, Alfonso, Spears, Jeffrey, Mir, Roser, Edginton, Andrea

“…The article Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients, written by Pierre…”
Get full text

Multidrug resistance protein 1 localization in lipid raft domains and prostasomes in prostate cancer cell lines by Gomà, Alba, Mir, Roser, Martínez-Soler, Fina, Tortosa, Avelina, Vidal, August, Condom, Enric, Pérez-Tomás, Ricardo, Giménez-Bonafé, Pepita

“…One of the problems in prostate cancer (CaP) treatment is the appearance of the multidrug resistance phenotype, in which ATP-binding cassette transporters such…”
Get full text